Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs VKTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZLAB Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 3–5 Matrix Metrics)

ZLAB Overall Winner 6-Pillar Tally: ZLAB 3 – 3 VKTX Matrix Metrics: ZLAB 3 – 5 VKTX

As of Nov 16, 2026, Zai Lab Limited (ZLAB) is the stronger overall head-to-head candidate over Viking Therapeutics, Inc (VKTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas VKTX carries 46.5/100 (HOLD) at $26.86 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile VKTX is in a Breakdown options structure phase (RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs VKTX
ZLAB NASDAQ Head-to-Head Winner
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
VKTX NASDAQ
Viking Therapeutics, Inc
Pharmaceutical Preparations
$26.86
-8.08% 1D
Market Cap $3.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 74% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $26.76 · SMA50: $29.17

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 3 – 3 VKTX)

Columns: Metric · ZLAB · VKTX
1. Valuation Multiples ZLAB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.8x N/M
2. Growth & Scale VKTX
Revenue Growth (YoY) -6.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $442M N/A
Market Cap $3.0B $3.8B
3. Profitability & Quality VKTX
Gross Margin 0.6% N/A
Operating Margin -63.0% 0.0%
Net Profit Margin -44.9% 0.0%
Return on Equity (ROE) -30.0% -96.4%
4. Balance Sheet & Cash Flow ZLAB
Cash Generation (TTM) -$262M EBITDA -$463M
Cash Flow Margin -59.3% EBITDA Mgn N/A
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $423M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VKTX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 58.4% (58th %ile) 164.2% (88th %ile)
Put/Call OI Skew Thin ADR Chain 0.15x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (3) vs VKTX (5)
Institutional Metric ZLAB VKTX Criterion Row Edge
Market Capitalization
Scale
$3.0B $3.8B Larger Scale VKTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-6.8% +0.0% Higher Growth VKTX
Operating Margin (TTM)
Profitability
-63.0% 0.0% Higher Margin VKTX
Net Profit Margin
Profitability
-44.9% 0.0% Higher Margin VKTX
Return on Equity (ROE)
Capital Efficiency
-30.0% -96.4% Higher ROE ZLAB
52-Week Range Position
Momentum
60% ($16–$29) 16% ($24–$43) Stronger Trend ZLAB
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 1.52β · 74% Vol Lower Realized Risk VKTX
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 46.5 / 100 (HOLD) Higher Composite ZLAB
Trailing 12M Revenue (USD)
Operating Scale
$442M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) -$463M ($423M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VKTX +3.95 pp
ZLAB: +2.76% · VKTX: +6.71%
3M Horizon ZLAB +12.71 pp
ZLAB: -6.8% · VKTX: -19.51%
6M Horizon ZLAB +32.73 pp
ZLAB: +26.35% · VKTX: -6.38%
1Y Horizon ZLAB +40.79 pp
ZLAB: +9.66% · VKTX: -31.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs VKTX. Trailing 12-month operating profitability (ZLAB -63.0% vs VKTX 0.0%) and valuation multiples (ZLAB N/M vs VKTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
VKTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-96.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VKTX BREAKDOWN
93d in phase · OBV NEUTRAL
Current IV 164.2%
IV Percentile 88th %ile
Put/Call OI Skew 0.15x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
VKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs VKTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Zai Lab Limited (ZLAB) is the stronger overall head-to-head candidate over Viking Therapeutics, Inc (VKTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas VKTX carries 46.5/100 (HOLD) at $26.86 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile VKTX is in a Breakdown options structure phase (RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VKTX leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with VKTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus N/A for VKTX. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VKTX.

ZLAB screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas VKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus VKTX (-96.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, VKTX carries 164.2% implied volatility (88th %ile, Extreme (>80th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.